A Clinical Study to Evaluate the Safety and Tolerability of JS001sc in Advanced Nasopharyngeal Carcinoma

Inclusion criteria

• . The subjects voluntarily participated in the study with full informed consent and signed written informed consent form;
• . Recurrent/metastatic nasopharyngeal carcinoma diagnosed histologically and/or cytologically,Patients with no loco-regional therapy or radical therapy of primary metastatic （UICC\&AJCC 8th edition) or recurrent nasopharyngeal carcinoma after radical therapy.No previous systematic treatment for recurrent or metastatic disease.
• . Patients with recurrent nasopharyngeal carcinoma after radical therapy must be satisfied that the disease recurrence more than 6 months after the last radiotherapy or chemotherapy.
• . There should be at least one measurable lesion according to RECIST V1.1 evaluation criteria. The lesions that have previously received radiotherapy should not be considered as target lesions unless there is definite progression after radiotherapy.
• . Age of 18-75 years (inclusive), male or female;
• . The physical status score is 0 or 1 on the Eastern Oncology Collaboration (ECOG) scale;
• . The expected survival is ≥3 months;
• . Major organ functions meet the following requirements.No blood transfusion or blood products, hematopoietic stimulating factors or other drugs were used to correct blood cell counts within 14 days prior to the examination：

Exclusion criteria